- Home
- EOG vs ALNY Comparison
EOG vs ALNY Comparison
Compare EOG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOG
- ALNY
- Stock Information
- Founded
- EOG 1985
- ALNY 2002
- Country
- EOG United States
- ALNY United States
- Employees
- EOG N/A
- ALNY N/A
- Industry
- EOG Oil & Gas Production
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- EOG Energy
- ALNY Health Care
- Exchange
- EOG Nasdaq
- ALNY Nasdaq
- Market Cap
- EOG 65.3B
- ALNY 59.2B
- IPO Year
- EOG N/A
- ALNY 2004
- Fundamental
- Price
- EOG $117.65
- ALNY $455.03
- Analyst Decision
- EOG Buy
- ALNY Strong Buy
- Analyst Count
- EOG 23
- ALNY 27
- Target Price
- EOG $141.55
- ALNY $420.73
- AVG Volume (30 Days)
- EOG 2.4M
- ALNY 1.1M
- Earning Date
- EOG 11-06-2025
- ALNY 10-30-2025
- Dividend Yield
- EOG 3.47%
- ALNY N/A
- EPS Growth
- EOG N/A
- ALNY N/A
- EPS
- EOG 10.30
- ALNY N/A
- Revenue
- EOG $22,798,000,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- EOG $2.07
- ALNY $58.97
- Revenue Next Year
- EOG $10.07
- ALNY $38.81
- P/E Ratio
- EOG $11.42
- ALNY N/A
- Revenue Growth
- EOG N/A
- ALNY 5.01
- 52 Week Low
- EOG $102.52
- ALNY $205.87
- 52 Week High
- EOG $138.18
- ALNY $469.81
- Technical
- Relative Strength Index (RSI)
- EOG 43.15
- ALNY 68.02
- Support Level
- EOG $116.57
- ALNY $444.66
- Resistance Level
- EOG $126.12
- ALNY $458.30
- Average True Range (ATR)
- EOG 2.48
- ALNY 11.15
- MACD
- EOG -0.32
- ALNY -4.41
- Stochastic Oscillator
- EOG 15.60
- ALNY 47.79
About EOG EOG Resources Inc.
EOG Resources is an oil and gas producer with acreage in several US shale plays, primarily in the Permian Basin and the Eagle Ford. At the end of 2024, it reported net proven reserves of 4.7 billion barrels of oil equivalent. Net production averaged roughly 1,062 thousand barrels of oil equivalent per day in 2024 at a ratio of 69% oil and natural gas liquids and 31% natural gas.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.